4.5 Article

Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole

出版社

SPRINGER
DOI: 10.1007/s10096-014-2230-8

关键词

-

资金

  1. Pfizer Pharma GmbH, Germany

向作者/读者索取更多资源

Direct treatment costs caused by candidemia in German intensive care unit (ICU) patients are currently unknown. We analyzed treatment costs and the impact of antifungal drug choice. Comprehensive data of patients who had at least one episode of candidemia while staying in the ICU between 01/2005 and 12/2010 were documented in a database using the technology of the Cologne Cohort of Neutropenic Patients (CoCoNut). A detailed analysis of all disease-associated treatment costs was performed. Patients treated with echinocandins (i.e., anidulafungin, caspofungin, micafungin) or fluconazole were analyzed separately and compared. Forty-one and 64 patients received echinocandins and fluconazole, respectively. The mean Acute Physiology and Chronic Health Evaluation (APACHE) IV score was 114 (95 % confidence interval [CI]: 106-122) vs. 95 (95 % CI: 90-101, p = < 0.001). Twenty-three (56 %) and 33 (52 %, p = 0.448) patients survived hospitalization, while 17 (41 %) and 22 (34 %, p = 0.574) survived one year after diagnosis. In the echinocandin and fluconazole groups, the mean costs per patient of ICU treatment were a,not sign20,338 (95 % CI: a,not sign12,893-27,883) vs. a,not sign11,932 (95 % CI: a,not sign8,016-15,849, p = 0.110), and the total direct treatment costs per patient were a,not sign37,995 (95 % CI: a,not sign26,614-a,not sign49,376) vs. a,not sign22,305 (95 % CI: a,not sign16,817-a,not sign27,793, p = 0.012), resulting in daily costs per patient of a,not sign1,158 (95 % CI: a,not sign1,036-a,not sign1,280) vs. a,not sign927 (95 % CI: a,not sign828-a,not sign1,026, p = 0.001). Our health economic analysis shows the high treatment costs of patients with candidemia in the ICU. Sicker patients had a prolonged hospitalization and were more likely to receive echinocandins, leading to higher treatment costs. Outcomes were comparable to those achieved in less sick patients with fluconazole.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据